Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma. (PubMed, Urol Oncol) - Sep 25, 2026 - "Our findings suggest that LVI and nodal positivity may help identify patients with high-risk MIUC who are more likely to benefit from adjuvant nivolumab. These pathological features may serve as practical markers for patient selection; however, further validation is required before clinical implementation."
Journal • Oncology • Solid Tumor • Urothelial Cancer
|
|
Hiroki Shimoda; Junji Yonese; Kosuke Takemura; Masaharu Inoue; Noboru Numao; Ryo Fujiwara; Ryosuke Oki; Takashi Tamiya; Tetsuya Urasaki; Yuji Miura
|